Sight Sciences, Inc.
SGHTNasdaqHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $77.4M | $79.9M | $81.1M | $71.3M | $49.0M | $27.6M |
| Operating income | −$37.1M | −$50.5M | −$57.3M | −$84.0M | −$51.5M | −$32.2M |
| Net income | −$38.4M | −$51.5M | −$55.5M | −$86.2M | −$63.0M | −$34.7M |
| Total assets | $115.3M | $142.8M | $166.7M | $213.1M | $280.2M | $72.8M |
| Total liabilities | $51.4M | $55.3M | $46.4M | $53.0M | $48.1M | $44.3M |
| Equity | $63.9M | $87.5M | $120.2M | $160.1M | $232.1M | −$88.8M |
| EPS (diluted) | $-0.74 | $-1.03 | $-1.14 | $-1.80 | $-2.36 | — |
| Shares out. | 51.3M | 49.6M | 48.4M | 47.6M | 47.5M | 9.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −48.0%
- Net margin
- −49.7%
- Return on equity
- −60.1%
- Return on assets
- −33.3%
- Return on capital (ROCE)
- −35.6%
- Liabilities / assets
- 44.5%
- Debt / equity
- 0.80×
- Book value / share
- $1.25
- Revenue growth (YoY)
- −3.1%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -5.95distress
- Accruals / assets
- −7.6%clean
- Beneish M-Score
- -3.01normal
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Kck Ltd.Passive (13G)Apr 8, 2026
- Blackrock, Inc.Passive (13G)Jan 21, 2026
- Long Focus Capital Management, LlcPassive (13G)May 15, 2025
- Encrantz StaffanActivist (13D)Mar 13, 2025
- Ubs Group AgPassive (13G)Aug 8, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Bauerlein AlisonOfficer — Chief Operating Officer | May 18, 2026 | Sell | 12,728 | $5.12 |
| Rodberg JamesOfficer — Chief Financial Officer | Apr 6, 2026 | Sell | 7,231 | $3.55 |
| Hayden Jeremy B.Officer — Chief Legal Officer | Apr 6, 2026 | Sell | 13,761 | $3.55 |
| Bauerlein AlisonOfficer — Chief Operating Officer | Apr 2, 2026 | Sell | 25,874 | $3.48 |
| Badawi DavidOfficer — Chief Technology Officer | Apr 2, 2026 | Sell | 8,168 | $3.48 |
| Taylor BrentonOfficer — EVP, Operations & R&D | Apr 1, 2026 | Sell | 2,869 | $3.70 |
| Badawi PaulOfficer — President and CEO | Apr 1, 2026 | Sell | 29,244 | $3.70 |
| Badawi DavidOfficer — Chief Technology Officer | Feb 19, 2026 | Option exercise | 21,270 | $0.23 |
| Badawi DavidOfficer — Chief Technology Officer | Feb 3, 2026 | Grant | 64,915 | $0.00 |
| Hayden Jeremy B.Officer — Chief Legal Officer | Feb 3, 2026 | Grant | 115,920 | $0.00 |
| Bauerlein AlisonOfficer — Chief Operating Officer | Feb 3, 2026 | Grant | 127,512 | $0.00 |
| Badawi PaulOfficer — President and CEO | Feb 3, 2026 | Grant | 154,560 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 862,599 | 3.5 | -7.9% |
| Apr 30, 2026 | 936,889 | 2.1 | -12.8% |
| Apr 15, 2026 | 1.1M | 5.7 | +0.8% |
| Mar 31, 2026 | 1.1M | 3.3 | -2.8% |
| Mar 13, 2026 | 1.1M | 1.9 | +10.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Regulation FD disclosureMay 6, 2026
- Regulation FD disclosureApr 23, 2026
- Regulation FD disclosureMar 30, 2026
- Results of operations · Regulation FD disclosureMar 4, 2026
- Entered a material agreementFeb 3, 2026
- Results of operationsJan 13, 2026
- Results of operations · Director / officer change · Regulation FD disclosureNov 6, 2025
- Regulation FD disclosure · Other material eventOct 17, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.